Gamma Knife Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029

American Brain Tumor Association 2021 report cites that cancer is the second largest cause for death globally responsible for the death of approximately 8.8 million patients. World Health Organization predicts the growth of cancer incidence to reach 70% in next 20 years. Gamma knife devices faces stringent market competition by other types of radiosurgery such as Linear Accelerator Systems (LINAC) and Cyclotron. They have meritorious features in comparison to gamma knife in treating larger tumor in larger areas of brain and other body parts and precisely target only the tumor cells, causing least harm to the surrounding healthy cells.

Gamma knife devices are employed for cancer treatment by indications such as benign tumors, malignant tumors, functional disorders, vascular disorders and ocular diseases. The performance of gamma knife devices as a therapy for the indication segment is elucidated as market estimation and data forecast.

The five major regional segment comprising of their major countries are covered under the geography segment:

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Latin America
• Mexico
• Brazil
• Rest of LATAM
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

Geographical segment for gamma knife devices consists of country cross sectional market estimation and data forecast for 2019-2029.

Technological evolution in the gamma knife devices such as the radiation doses utilized, composite isocenters and automated shielding for enhanced device safety and accuracy are studied in the company profiles section. Latest merger and acquisition within the premier players are mentioned under recent news coverage. The competitive landscape gives information about the existing monopoly in gamma knife devices e.g. Elekta AB and ambitious business tactics applied by other major players to capture the market. The foremost leaders in the development of gamma knife devices for cancer treatment are Elekta AB, American Shared Hospital Services, Hokai, Cyber Medical Corporation Limited, ET Medical Group, Huiheng Medical, Inc., Masep Infini Global, Inc., Nordion, Inc. and Varian Medical Systems, Inc.

Based on indications, the gamma knife devices market is categorized into:

• Benign Tumors
• Malignant Tumors
• Functional Disorders
• Vascular Disorders
• Ocular Diseases

Gamma knife is a radiation surgery therapy employed for the treatment of brain tumors, epilepsy, arteriovenous malformation, and trigeminal neuralgia. The procedure consists of delivering finely focused radiation of high dose on the target cells and its high degree of precision and accuracy prohibits damage to the surrounding healthy cells. It is used for the treatment of abnormalities measuring 1 inch in diameter. Malignant tumors have a big market in the indications segment as a result of rising prevalence of patients suffering with malignant cancers. Additionally gamma knife therapy finds huge application in the treatment of malignant tumors owing to its safety features and accuracy. Fractionated external radiation therapy is considered as an adjuvant therapy for the treatment of primary brain tumor. Teletherapy a kind of gamma knife radiosurgery is finding huge attraction for the treatment of ocular diseases such as choroidal melanoma and uveal melanoma. Low radiation gamma therapy is also utilized to reduce the intraocular pressure for the treatment of glaucoma. The chief players in the global gamma knife devices market are American Shared Hospital Services, Cyber Medical Corporation Limited, ET Medical Group, Elekta AB, Hokai, Huiheng Medical, Inc., Masep Infini Global, Inc., Nordion, Inc. and Varian Medical Systems, Inc.

For the purpose of this study, the global gamma knife devices market is categorized into the following regional and country specific markets:

• North America
• United States
• Canada
• Europe
• United Kingdom
• Germany
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

Center for Disease Control and Prevention 2014 survey research finding claims that every year there are approximately 1.5 million cases of invasive cancer out of which around 590,000 people die due to cancer. Rising prevalence of cancer and increasing demand for non-invasive radiation therapy drives the gamma knife devices market in North America. Western Europe is a rapidly growing market due to presence of cardinal players pioneering in manufacture of gamma knife devices. Additionally the effective cancer treatment guidelines formulated by EU have favored radiation therapy as an adjuvant therapy for the treatment of cancer that adds to the market growth in Europe. Asia Pacific dominates the gamma knife devices market on account of rising prevalence of brain tumors, increasing specialty clinics providing effective cancer diagnosis, and treatment. Japan has invested huge in the research and development of the radiation therapy devices utilized for cancer treatment.


This product will be delivered within 2 business days.